Dongkook Pharmaceutical Achieves Record High Sales Last Year... Operating Profit Up 14.6% YoY

All Business Divisions Show Balanced Growth

Dongkook Pharmaceutical achieved its highest-ever sales last year.

Exterior view of Dongkook Pharmaceutical headquarters. [Photo by Dongkook Pharmaceutical]

Dongkook Pharmaceutical announced on the 9th that its consolidated sales last year were tentatively estimated at 661.6 billion KRW, an 11.4% increase compared to the previous year. This is the highest sales figure in the company's history. Operating profit during the same period rose by 14.9% to 72.7 billion KRW.

On a quarterly basis, sales in the fourth quarter of last year grew by 10.6% year-on-year to 166.4 billion KRW, and operating profit increased by 6.9% to 17.4 billion KRW.

Dongkook Pharmaceutical explained that all business divisions showed balanced growth last year. The OTC (over-the-counter) segment saw increased demand for all products due to the 'With Corona' effect, resulting in higher sales compared to the previous year. Specifically, the wound treatment product 'Madecassol' and the venous circulation enhancer 'Sensia' showed high growth rates.

In the ETC (ethical drugs) segment, chronic disease-related internal medicine drugs such as the hyperlipidemia combination drugs 'Rosutanjet', 'Pitaron-F', and 'Atovanduo' led growth. Dongkook Pharmaceutical plans to gradually strengthen its product lineup by launching diabetes treatments whose patents have expired. Additionally, it aims to secure future pipelines through open innovation.

The overseas business division saw significant sales growth of the anticancer drug 'Lorelindeponju', used for prostate cancer and precocious puberty, in the Latin American region. The antibiotic raw material 'Teicoplanin' also increased its market share in Turkey, Brazil, Japan, and other countries. The general anesthetic Propofol injection showed growth in the Middle East region.

In the healthcare division, balanced growth was observed across all businesses, including beauty (cosmetics), lifestyle health, and online. The beauty business maintained stable growth domestically with the cosmetics brand 'Centellian24'. As of December last year, cumulative sales of Centellian24 brand products were 41 million units of Madeca Cream, 13.5 million bottles of Mela Capture Ampoule, and 69 million sheets of mask packs.

In the lifestyle health business, the company reported growth with products such as 'Sensian', 'Dentrix', and 'Medipatch'. Dongkook Pharmaceutical is strengthening its consumer direct sales (D2C) channels centered on its official healthcare online shopping mall and enhancing business-to-business (B2B) channels in its online business.

This content was produced with the assistance of AI translation services.